Inhibition of bromodomain and extra-terminal proteins targets constitutively active NFκB and STAT signaling in lymphoma and influences the expression of the antiapoptotic proteins BCL2A1 and c-MYC
Authors:
Open Access
- 27 August 2024
- journal article
- research article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 22 (1) , 1-15
Abstract
The antiapoptotic protein BCL2A1 is highly, but very heterogeneously expressed in Diffuse Large B-cell Lymphoma (DLBCL). Particularly in the context of resistance to current therapies, BCL2A1 appears to play an important role in protecting cancer cells from the induction of cell death. Reducing BCL2A1 levels may have therapeutic potential, however, no specific inhibitor is currently available. In this study, we hypothesized that the signaling network regulated by epigenetic readers may regulate the transcription of BCL2A1 and hence that inhibition of Bromodomain and Extra-Terminal (BET) proteins may reduce BCL2A1 expression thus leading to cell death in DLBCL cell lines. We found that the mechanisms of action of acetyl-lysine competitive BET inhibitors are different from those of proteolysis targeting chimeras (PROTACs) that induce the degradation of BET proteins. Both classes of BETi reduced the expression of BCL2A1 which coincided with a marked downregulation of c-MYC. Mechanistically, BET inhibition attenuated the constitutively active canonical nuclear factor kappa-light-chain-enhancer of activated B-cells (NFκB) signaling pathway and inhibited p65 activation. Furthermore, signal transducer of activated transcription (STAT) signaling was reduced by inhibiting BET proteins, targeting another pathway that is often constitutively active in DLBCL. Both pathways were also inhibited by the IκB kinase inhibitor TPCA-1, resulting in decreased BCL2A1 and c-MYC expression. Taken together, our study highlights a novel complex regulatory network that links BET proteins to both NFκB and STAT survival signaling pathways controlling both BCL2A1 and c-MYC expression in DLBCL. Graphical AbstractKeywords
Funding Information
- Johann Wolfgang Goethe-Universität, Frankfurt am Main
This publication has 61 references indexed in Scilit:
- JAK–STAT signalling shapes the NF‐κB response in CLL towards venetoclax sensitivity or resistance via Bcl‐XLMolecular Oncology, 2023
- It's time to die: BH3 mimetics in solid tumorsBiochimica et Biophysica Acta (BBA) - Molecular Cell Research, 2021
- JQ1 inhibits tumour growth in combination with cisplatin and suppresses JAK/STAT signalling pathway in ovarian cancerEuropean Journal of Cancer, 2020
- Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugsEBioMedicine, 2018
- Experimental Characterization of the Binding Affinities between Proapoptotic BH3 Peptides and Antiapoptotic Bcl‐2 ProteinsChemMedChem, 2018
- DUB3 Promotes BET Inhibitor Resistance and Cancer Progression by Deubiquitinating BRD4Molecular Cell, 2018
- Genetic and Functional Drivers of Diffuse Large B Cell LymphomaCell, 2017
- Discovery and Characterization of Super-Enhancer-Associated Dependencies in Diffuse Large B Cell LymphomaCancer Cell, 2013
- BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-MycCell, 2011
- Differential Targeting of Prosurvival Bcl-2 Proteins by Their BH3-Only Ligands Allows Complementary Apoptotic FunctionMolecular Cell, 2005